Biocon has been included in S&P’s Sustainability Yearbook 2024 for the second consecutive year, based on the S&P Global Corporate Sustainability Assessment (CSA) of Biocon and Biocon Biologics for 2023. Sustainability is integral to Biocon’s business purpose, and the Group is executing a progressive Environment, Social and Governance (ESG) strategy aligned with stakeholder expectations and business objectives.
Biocon’s S&P Global ESG score was 63 versus 52 previously, placing it among the Top 10 global biotechnology companies from within the 300 companies that were assessed. The S&P Global CSA, a leading corporate sustainability database, enables companies to directly report key sustainability metrics and benchmark their sustainability performance on a wide range of industry-specific economic, environmental, and social criteria.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
